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Paradoxical growth was noted in RPMI 1640 and antibiotic medium 3 in the case of 14 and 1 of 15 Candida
tropicalis strains, respectively, at a caspofungin concentration of 12.5 g/ml using minimum fungicidal con-
centration tests. Time-kill assays showed that against isolates killed at lower concentrations, caspofungin at a
concentration of 12.5 g/ml was only fungistatic.
The growing body of data shows that some Candida strains,
which are inhibited by a low concentration of echinocandin
antifungals, exhibit growth in the presence of high concentra-
tions of the drugs (2, 9, 10). The frequencies of this paradoxical
growth (PG) were found to vary (observed for 10 to 90% of
strains) among the most frequently isolated Candida species
(2, 7, 9). The only species found to grow in the presence of a
high concentration of all three marketed echinocandins, i.e.,
caspofungin (CAS), micafungin (MICA), and anidulafungin,
was C. tropicalis (2).
Our aim was to examine the occurrence of PG in clinical C.
tropicalis isolates in vitro by means of MIC and minimum
fungicidal concentration (MFC) tests as well as by determining
the killing dynamics in time-kill experiments.
(This work was presented in part at the 8th European
Congress of Chemotherapy and Infection, Budapest, Hungary,
2006 [poster no. 212].)
Fifteen C. tropicalis clinical isolates and the C. tropicalis
strain ATCC 750 were used. The CAS (Merck) MICs and
MFCs were determined according to the CLSI (formerly NCCLS)
method with RPMI 1640 medium (6) and antibiotic medium 3
(AM3; Fluka), as recommended previously (1). In MFC tests,
the starting inoculum was increased 100-fold (to 105 CFU/ml)
(5). The CAS concentration range was 0.024 to 12.5 g/ml.
CAS MICs were read after 24 h, using the partial inhibition
criterion (5). After 24 and 48 h, the entire contents of each well
containing drug concentrations above the MIC was plated onto
Sabouraud dextrose agar (5).
Time-kill studies were performed following the method de-
scribed previously (4). CAS concentrations ranged from 1 to
512 times the MIC (0.024 to 12.5 g/ml). Samples were re-
moved at 0, 2, 4, 8, 12, 24, and 48 h and plated onto Sabouraud
dextrose agar. Plates were incubated at 35°C for 48 h, in both
the MFC and the time-kill tests, and fungicidal activity was
defined as a 99.9% reduction in viable CFU/ml compared to
that of the starting inoculum (4, 5).
In another experiment, 1 g/ml of amphotericin B (AMB)
(Sigma), fluconazole (FLC) (Pfizer), or flucytosine (5FC)
(Sigma) was added to the test tubes containing 12.5 g/ml of
CAS. All assays were repeated at least twice.
In both the RPMI 1640 medium and AM3, MICs were 0.024
g/ml for all strains, regardless of the starting inoculum. In
RPMI 1640 medium, PG was detected in two cases (isolates 4
and 15) at 12.5 g/ml CAS, using the standard inoculum. In the
case of the elevated starting inoculum, partial growth was de-
tected in all wells. In MFC tests, all isolates except number 7
grew at 12.5 g/ml (Fig. 1). Six of fifteen and 7 out of 15
isolates also grew at 6.25 g/ml after 24 and 48 h of incubation,
respectively.
In AM3, isolate number 6 showed PG after the high-con-
centration inoculum was used but not with the standard start-
ing inoculum. In the MFC test, this strain also grew at 6.25 and
12.5 g/ml. Fifteen strains were killed by concentrations0.09
g/ml CAS (4 times the MIC) after 24 h.
The strains tested in the time-kill experiments together with
their AMB, FLC, and 5FC MICs are listed in Table 1; repre-
sentative kill curves with RPMI 1640 medium are shown in
Fig. 2.
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TABLE 1. MICs and PG patterns of strains used in this studya
Strain
MIC (g/ml)c PG at 6.25 and12.5 g/ml after d:
AMB FLC 5FC 24 h 48 h
4 2 0.5 0.12 12.5 Both
5 2 0.25 0.12 Both Both
6b 2 0.25 0.12 Both Both
7 2 0.25 0.12 None None
8 2 0.5 0.12 12.5 12.5
13 2 0.5 0.12 12.5 12.5
15 2 0.25 0.12 Both Both
ATCC 750 1 1 0.12 Both Both
a Strains used in the time-kill experiments are shown with their MICs for
AMB, FLC, and 5FC and their PG patterns in MFC tests after 24 and 48 h in
RPMI 1640 medium.
b This isolate also showed PG in AM3.
c MICs were determined according to the CLSI method (6).
d Both, PG was observed at both concentrations. None, PG was observed at
neither concentration.
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Time-kill curves confirmed the PG of seven of the clinical
isolates found to grow paradoxically by using MFC determina-
tions in both media. Ranges of CFU changes varied between
lg0.36 tolg1.3 andlg1.51 tolg0.63 CFU/ml after 24 and
48 h, respectively. Generally, CAS proved to be fungicidal at
lower (3.12 g/ml) concentrations, but at high concentra-
tions (6.25 to 12.5 g/ml), only fungistatic activity was observed
(Fig. 2). When we retested the strains growing at 12.5 g/ml,
we obtained essentially the same CAS kill curves.
The killing patterns obtained using the MFC and the time-
kill methods (except for isolate 4 and the ATCC 750 strain in
RPMI 1640 medium) were identical for the strains tested. C.
tropicalis ATCC 750 grew at all CAS concentrations tested in
the MFC tests, after both 24 and 48 h. In the time-kill test, this
strain grew only at 512 times the MIC (12.5 g/ml), but yeasts
were killed at 1 to 256 times the MIC (0.19 to 6.25 g/ml) for
CAS concentrations after 24 h. A similar discrepancy, but to a
lesser extent, was found for isolate number 4.
In the time-kill assay, the presence of FLC, but not of AMB
or 5FC, at 1 g/ml, regardless of the medium used, eliminated
PG even after 24 h, for all clinical isolates (Fig. 3). In contrast,
FIG. 1. Growth distribution of the C. tropicalis clinical isolates (no. 1 to 15) at different concentrations of CAS (0.4 to 12.50 g/ml) in the MFC
tests after 24 and 48 h in RPMI 1640 medium.
FIG. 2. Representative time-kill plots of C. tropicalis isolate number
15 (MIC, 0.024g/ml) following exposure to CAS in RPMI 1640 medium.
Filled diamonds, 512 times the MIC; asterisks, 256 times the MIC; filled
triangles, 128 times the MIC; open circles, 32 times the MIC; filled
squares, 8 times the MIC; filled circles, 2 times the MIC; open triangles,
1 times the MIC; open diamonds, drug-free control. Each datum point
represents the mean of two independent experiments.
FIG. 3. Time-kill plots of C. tropicalis isolate number 4 following
exposure to CAS alone and CAS combined with other antifungals in
RPMI 1640 medium. Open diamonds, drug-free control; filled dia-
monds, CAS (12.5 g/ml) alone; open triangles, FLC (1 g/ml) alone;
filled triangles, CAS (12.5 g/ml) plus FLC (1 g/ml); open circles,
AMB (1 g/ml) alone; filled circles, CAS (12.5 g/ml) plus AMB (1
g/ml); open squares, 5FC (1 g/ml) alone; filled squares, CAS (12.5
g/ml) plus 5FC (1 g/ml). Each datum point represents the mean of
two separate experiments with similar results.
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in the case of C. tropicalis ATCC 750, the combination of CAS
with AMB, but not with FLC or 5FC, eliminated PG.
C. tropicalis is a species that shows PG equally in the pres-
ence of CAS, MICA, and anidulafungin (2). Moreover, Pappas
et al. observed more treatment failures with daily doses of 150
mg MICA but not with daily doses of 100 mg MICA or 70 mg
CAS (8), in cases of patients infected with several Candida
species including C. tropicalis. They suggested that PG may
contribute to this phenomenon. Similar in vivo effects were
observed for infections by Aspergillus fumigatus and C. albicans
(3, 11).
In our work, visible PG in RPMI 1640 medium was noted in
the case of 2/15 (13%) and 14/15 (93%) isolates in the MIC
and MFC tests, respectively. Similar to the results reported by
Pai et al. (7), we found that the use of AM3 almost totally
eliminated this phenomenon; a single isolate showed PG in the
MFC tests but none in the MIC tests.
Killing curves obtained with high-concentration CAS clearly
indicated that viable C. tropicalis cells were present at all times
during the time-kill experiment; at very high concentrations,
CAS practically became fungistatic rather than fungicidal. The
time-kill method was superior to the MFC test for the ATCC
strain.
In conclusion, PG could be reliably predicted by the time-kill
and MFC tests but not by the MIC test. This may have future
implications, because based on these and earlier data (2, 3, 11),
the clinical relevance of PG cannot be excluded, suggesting
that high doses of echinocandins may lead to treatment failure
in certain clinical situations (8).
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